Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
Methods of T Cell Depletion Trial (MoTD)
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 400
- Registration Number
- NCT04888741
- Locations
- 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Bristol Haematology and Oncology Centre, Bristol, United Kingdom
🇬🇧University Hospital of Wales, Cardiff, Wales, United Kingdom
Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 120
- Registration Number
- NCT04849533
- Locations
- 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
- Conditions
- Interventions
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04776850
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Yi Luo
- Target Recruit Count
- 46
- Registration Number
- NCT04688021
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Haploidentical HCT for Severe Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04558736
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 160
- Registration Number
- NCT04547049
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China
🇨🇳The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
🇨🇳The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
- Conditions
- Refractory Malignant Peripheral Nerve Sheath TumorEwing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent RhabdomyosarcomaRefractory Malignant Solid NeoplasmDesmoplastic Small Round Cell TumorRecurrent Malignant Peripheral Nerve Sheath TumorRefractory Desmoplastic Small Round Cell TumorRecurrent Desmoplastic Small Round Cell TumorRecurrent Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04530487
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04521946
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
- Conditions
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 114
- Registration Number
- NCT04509791
- Locations
- 🇧🇪
Universitair ziekenhuis Brussel, Brussels, Belgium
🇧🇪Universitaire Ziekenhuizen Leuven, Leuven, Belgium
🇫🇮Helsinki University Hospital Children and Adolescents, Helsinki, Finland
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
- Conditions
- Interventions
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 21
- Registration Number
- NCT04395222
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.